Scholarlink

Background <p>To present the one-year outcomes of accelerated corneal collagen cross-linking (CXL) with 0.25% riboflavin in the management of progressive keratoconus in the East Asian population.</p> Methods <p>A retrospective analysis was performed on twenty-four patients (32 eyes) diagnosed with progressive keratoconus treated in Taiwan. Exclusion criteria included corneas with a stromal thickness of less than 400&#xa0;μm. A 15-min soak with 0.25% riboflavin was followed by UVA light exposure at 18&#xa0;mW/cm<sup>2</sup> for 5&#xa0;min, achieving a total energy of 5.4&#xa0;J/cm<sup>2</sup>. Corrected distance visual acuity, corneal topography, subjective refraction, endothelial cell density, corneal thickness were evaluated at baseline, 1, 3, 6, and 12&#xa0;months postoperatively. The primary efficacy criterion was the changes in maximum keratometry (Kmax) at the 12-month follow-up.</p> Results <p>The mean Kmax decreased from 61.74 ± 9.9 to 60.05 ± 9.1 D at one-year follow-up (<i>P</i> = 0.002). Central corneal pachymetry decreased significantly from 464.16 ± 28.6 to 442.73 ± 87.6&#xa0;μm (<i>P</i> &lt; 0.001) at one year. The mean demarcation line depth was 375.91 ± 53.4&#xa0;μm at one-month follow-up. Mean corrected distance visual acuity, manifest refraction and endothelial cell density remained unchanged.</p> Conclusions <p>Our findings demonstrate the safety and efficacy of accelerated CXL with 0.25% riboflavin for progressive keratoconus, providing an effective option in clinical management.</p> Trial registration <p>This study retrospectively registered and approved by the Institutional Review Board (IRB) of the Shin Kong Wu Ho-Su Memorial Hospital. (IRB number: 20240403R).</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Outcome of accelerated corneal cross-linking with 0.25% riboflavin in progressive keratoconus patients

  • 期刊论文

  • 发表日期：

    2026年3月18日

查看全文
  • CyuanYi Yeh,
  • KuanI Huang,
  • KaiTing Katy Liang,
  • ChaoChien Hu,
  • ShengFu Cheng

摘要

Background

To present the one-year outcomes of accelerated corneal collagen cross-linking (CXL) with 0.25% riboflavin in the management of progressive keratoconus in the East Asian population.

Methods

A retrospective analysis was performed on twenty-four patients (32 eyes) diagnosed with progressive keratoconus treated in Taiwan. Exclusion criteria included corneas with a stromal thickness of less than 400 μm. A 15-min soak with 0.25% riboflavin was followed by UVA light exposure at 18 mW/cm2 for 5 min, achieving a total energy of 5.4 J/cm2. Corrected distance visual acuity, corneal topography, subjective refraction, endothelial cell density, corneal thickness were evaluated at baseline, 1, 3, 6, and 12 months postoperatively. The primary efficacy criterion was the changes in maximum keratometry (Kmax) at the 12-month follow-up.

Results

The mean Kmax decreased from 61.74 ± 9.9 to 60.05 ± 9.1 D at one-year follow-up (P = 0.002). Central corneal pachymetry decreased significantly from 464.16 ± 28.6 to 442.73 ± 87.6 μm (P < 0.001) at one year. The mean demarcation line depth was 375.91 ± 53.4 μm at one-month follow-up. Mean corrected distance visual acuity, manifest refraction and endothelial cell density remained unchanged.

Conclusions

Our findings demonstrate the safety and efficacy of accelerated CXL with 0.25% riboflavin for progressive keratoconus, providing an effective option in clinical management.

Trial registration

This study retrospectively registered and approved by the Institutional Review Board (IRB) of the Shin Kong Wu Ho-Su Memorial Hospital. (IRB number: 20240403R).